Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$60 Mln
P/E Ratio
--
P/B Ratio
0.34
Industry P/E
--
Debt to Equity
0.02
ROE
-0.54 %
ROCE
-52.6 %
Div. Yield
0 %
Book Value
5.2
EPS
-2.37
CFO
$--
EBITDA
$--
Net Profit
$--
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Acrivon Therapeutics, Inc. (ACRV)
| -67.11 | -63.06 | -64.64 | -79.18 | -- | -- | -- |
|
BSE Sensex
| 2.39 | 4.18 | 4.86 | 8.78 | 11.89 | 20.62 | 11.13 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
|
|---|---|---|
|
Acrivon Therapeutics, Inc. (ACRV)
| 22.16 | -57.29 |
|
S&P Small-Cap 600
| 7.01 | 13.89 |
|
BSE Sensex
| 8.10 | 18.74 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.73 | 9,808.03 | 20.22 | 23.13 | |
| 284.42 | 8,956.09 | 22.08 | 58.42 | |
| 26.83 | 9,559.25 | -- | -28.77 | |
| 103.38 | 10,030.35 | 30.81 | 14.16 |
Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder... identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response, or DDR, pathways; and ACR-2316, a dual WEE1/PKMYT1 inhibitor which in phase 1 clinical trial to assess the safety and tolerability. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts. Address: 480 Arsenal Way, Watertown, MA, United States, 02472 Read more
Co-Founder, Chairman of the Board, CEO, President & Acting Chief Scientific Officer
Dr. Peter Blume-Jensen M.D., Ph.D.
Co-Founder, Chairman of the Board, CEO, President & Acting Chief Scientific Officer
Dr. Peter Blume-Jensen M.D., Ph.D.
Headquarters
Watertown, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Acrivon Therapeutics, Inc (ACRV) stood at $ 197 Mln as on 31-Dec-24
The share price of Acrivon Therapeutics, Inc (ACRV) is $1.98 (NASDAQ) as of 23-Apr-2025 14:38 EDT. Acrivon Therapeutics, Inc (ACRV) has given a return of -79.18% in the last 1 years.
Acrivon Therapeutics, Inc (ACRV) has a market capitalisation of $ 60 Mln as on 22-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Acrivon Therapeutics, Inc (ACRV) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Acrivon Therapeutics, Inc (ACRV) and enter the required number of quantities and click on buy to purchase the shares of Acrivon Therapeutics, Inc (ACRV).
Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response, or DDR, pathways; and ACR-2316, a dual WEE1/PKMYT1 inhibitor which in phase 1 clinical trial to assess the safety and tolerability. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts. Address: 480 Arsenal Way, Watertown, MA, United States, 02472
The CEO & director of Dr. Peter Blume-Jensen M.D., Ph.D.. is Acrivon Therapeutics, Inc (ACRV), and CFO & Sr. VP is Dr. Peter Blume-Jensen M.D., Ph.D..
There is no promoter pledging in Acrivon Therapeutics, Inc (ACRV).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,012
|
|
|
990
|
|
|
974
|
|
|
896
|
| Acrivon Therapeutics, Inc. (ACRV) | Ratios |
|---|---|
|
Return on equity(%)
|
-54.07
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Acrivon Therapeutics, Inc (ACRV) was $0 Mln.
$-0.05
(
